HDRN Canada

Scientific Director and CEO’s Report

**November 15, 2023**

# Section 1: High Level Progress Update

## Key progress since the last board meeting:

HDRN Canada hosted an in-person meeting with several Working Groups (WGs) and Teams on October 4-5. Network members met in-person to develop Work Plans for the coming year, strategize within and across different teams, begin consultations on our IDEA strategy, and participate in a workshop on The First Nations Principles of OCAP®.

HDRN Canada submitted a funding proposal to the Canadian Drug Agency Transition Office (CDATO). This will support the development of select tables from the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) at five sites (BC, AB, MB, ON, and CIHI), and enable us to determine the benefits of conducting multi-regional studies using a CDM, as compared with the existing practice.

HDRN Canada was invited to join the Federal-Provincial-Territorial Digital Health and Data working group, which will advance the Action Plan endorsed by First Ministers during their October meeting in PEI.

## Major milestones for the coming quarter:

The re-development of new and revised key performance indicators (KPIs) from each of the WGs, Teams, and Council will be completed by November/December 2023.

HDRN Canada’s IDEA Strategy facilitation process is underway. Focus groups are currently taking place with each WG, Team, Leads, Exec, and the Board. Roundtable sessions will take place in January 2024 to synthesize input, with a final report expected by March/April 2024.

The DASH Operating Model Review is underway by external consultants with the final report expected by December 2023.

## Anticipated and ongoing challenge

While the IDEA Strategy is focused on further embedding IDEA within HDRN Canada, there is a challenge of scope creep and the potential for member organizations to feel HDRN Canada is dictating their activities. This will require ongoing attention and conversation.